Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570001 | 0.91 | OXTR (0.34) | KAT6AKAT5MMP2MMP9MMP8 | |
| SCHEMBL2411042 | 0.91 | HTR6 (0.33) | KAT6AKAT5HTR2CSLC6A4F2 | |
| SCHEMBL2409441 | 0.90 | HTR2C (0.35) | KAT6AKAT5MMP2MMP9MMP8 | |
| SCHEMBL1834426 | 0.88 | HTR2C (0.33) | KAT6AKAT5HTR2CSLC6A4HTR2A | |
| SCHEMBL2194090 | 0.88 | PTGDR2 (0.33) | MMP2MMP9MMP8MMP13ATM | |
| SCHEMBL1832665 | 0.88 | RORC (0.35) | KAT6AKAT5HTR2CSLC6A4F2 | |
| SCHEMBL2413759 | 0.88 | RORC (0.36) | KAT6AKAT5HTR2CSLC6A4HTR2A | |
| SCHEMBL1832149 | 0.87 | HTR2C (0.33) | KAT6AKAT5HTR2CSLC6A4F2 | |
| SCHEMBL4420269 | 0.87 | HTR6 (0.37) | HTR2CSLC6A4F2HTR2AKAT8 | |
| SCHEMBL1832615 | 0.86 | TACR1 (0.33) | HTR2CSLC6A4HTR2ASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2318390-A1 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010024451-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172275-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | KAT6A 689/4885KAT5 1523/4885MMP2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.